Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Sclnow Biotechnology Co., Ltd.
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03176498CT.gov Human Umbilical Cord Mesenchymal Stem Cell Therapy (19#iSCLife®-CI) for Cerebral Infarction Patients in Convalescent Period. | — | Suspended | — | — | — |
NCT02411903CT.gov The Dynamic Effect of Non-cytochrome P450 Isoenzyme 3A4（CYP3A4）-Metabolized and Cytochrome P450 Isoenzyme 3A4（CYP3A4）-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cerebral Infarction
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Atorvastatin (this asset) | Sclnow Biotechnology Co., Ltd. | Approved | BB · 65 |
| Cilostazol | Asan Medical Center | P4 | BBB |
| Aspirin | Sclnow Biotechnology Co., Ltd. | P4 | BBB |
| Sovateltide | Pharmazz, Inc. | P4 | BBB |
| Clopidogrel | The Second Hospital of Anhui Medical University | P4 | BBB |
| Human Urinary Kallidinogenase | Huisheng Chen | P4 | BB |
| Erigeron | Guangzhou University of Traditional Chinese Medicine | P4 | BB |
| Hua Tuo Zai Zao Wan | Guangzhou University of Traditional Chinese Medicine | P4 | BB |
| Triflusal | Gangnam Severance Hospital | P4 | BB |
+41 more in the Cerebral Infarction cohort
Other indications for Atorvastatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Inherited Lipid Metabolism Disorder | — | P4 | A · 83 |
| Hyperlipidemia | — | P4 | BBB · 79 |
| Cardiovascular Disorder | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Atorvastatin in Cerebral Infarction. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/atorvastatin-cerebral-infarction
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →